ProfileGDS5678 / 1455052_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 94% 94% 94% 94% 92% 93% 93% 93% 94% 94% 94% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9169693
GSM967853U87-EV human glioblastoma xenograft - Control 28.2041394
GSM967854U87-EV human glioblastoma xenograft - Control 38.2678294
GSM967855U87-EV human glioblastoma xenograft - Control 48.2006994
GSM967856U87-EV human glioblastoma xenograft - Control 58.1790294
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.4427592
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.6143893
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.7192193
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.8839893
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.0548994
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.9675794
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.1329694
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.851393
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9318693